注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Nuvalent Inc是一家臨床前階段的生物製藥公司,專注於為癌症患者創造精確的靶向治療。該公司正在推進一系列候選產品,連同由ROS原癌基因1(ROS1)和間變性淋巴瘤激酶(ALK)的基因組改變驅動的癌症平行計劃,以及多個研發階段的研究計劃。其主要候選產品NVL-520是一種ROS1選擇性抑製劑,旨在應對緊急治療耐藥、中樞神經系統(CNS)相關不良事件和腦轉移的臨床挑戰。該公司的候選產品還包括NVL-655,它是一種腦穿透性ALK選擇性抑製劑,旨在解決緊急治療耐藥、CNS相關不良事件和可能限制第一代、二代和三代ALK抑製劑使用的腦轉移的臨床挑戰。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Matthew D. Shair | 54 | 2017 | Founder, Head of Scientific Advisory Board & Director |
James R. Porter | 47 | 2020 | CEO, President & Director |
Anna Protopapas | 58 | 2022 | Independent Chairman |
Sapna Srivastava | 52 | 2021 | Independent Non-Executive Director |
Emily Drabant Conley | 41 | 2022 | Independent Director |
Joseph Pearlberg | 58 | 2021 | Independent Non-Executive Director |
Alexander Drilon | - | 2021 | Member of Scientific Advisory Board |
Cameron A. Wheeler | 44 | 2017 | Independent Non-Executive Director |
Andrew A. F. Hack | 49 | 2021 | Independent Non-Executive Director |
Aaron Hata | - | - | Member of Scientific Advisory Board |
Nancy Kohl | - | - | Member of Scientific Advisory Board |
D. Ross Camidge | - | - | Member of Scientific Advisory Board |
D. Gary Gilliland | 68 | 2021 | Independent Non-Executive Director |
Michael L. Meyers | 72 | 2022 | Independent Director |
Pasi Antero Janne | - | - | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核